Safety & Monitoring
-
what MHI monitors
-
why monitoring matters
-
when treatment is adjusted, paused, or referred onward
Treatment only makes sense when it is monitored properly
Why monitoring matters
-
track benefit over time
-
detect side effects early
-
avoid overtreatment
-
guide treatment changes
-
decide whether treatment continues
What is monitored
-
symptoms and clinical response
-
testosterone where relevant
-
haematocrit / haemoglobin
-
PSA where relevant
-
cardiovascular and metabolic context
-
tolerability and administration issues
Haematocrit and erythrocytosis
-
TRT can raise haematocrit
-
sleep apnoea, smoking, and dehydration matter
-
higher results may need dose reduction
-
treatment may need to pause
-
further action is sometimes needed
Follow-up is used to assess benefit, tolerability, blood results, and whether treatment should be adjusted, paused, or referred onward.
PSA and prostate review
-
PSA reviewed where relevant
-
trends matter more than one value
-
concerning change needs review
-
onward referral may be needed
Estradiol and gynecomastia
-
checked when clinically relevant
-
symptoms and context matter
-
not every high result needs treatment
-
avoid over-suppression
-
dose changes may help first
Sleep apnoea and cardiovascular caution
-
untreated sleep apnoea matters
-
smoking and CV risk matter
-
some men need broader review first
-
others need closer monitoring
When treatment may be adjusted or paused
-
rising haematocrit
-
significant side effects
-
testosterone levels running too high
-
concerning PSA change
-
worsening sleep apnoea or oedema
-
cardiovascular concerns
-
unclear clinical benefit